UE 2343

Drug Profile

UE 2343

Alternative Names: UE2343; Xanamem

Latest Information Update: 08 Dec 2015

Price : $50

At a glance

  • Originator University of Edinburgh
  • Developer Actinogen Medical; University of Edinburgh
  • Class Antidementias; Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 29 Sep 2015 Efficacy data from a phase I trial in Alzheimer's disease released by Actinogen Medical
  • 16 Apr 2015 Actinogen Medical plans a phase II trial for Alzheimer's disease in Australia, New Zealand, United Kingdom and USA (PO) (NCT02727699)
  • 24 Feb 2015 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top